Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Mirikizumab Solution (LY3074828) in Healthy Participants
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to assess the safety and tolerability of mirikizumab (LY3074828) solution formulation administered as a single injection compared with two injections under the skin in healthy participants. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 15 weeks.
Official title: An Adaptive Two-Stage Bioequivalence Study of Subcutaneous Injections of Mirikizumab Solution in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
450
Start Date
2026-03
Completion Date
2027-02
Last Updated
2026-03-19
Healthy Volunteers
Yes
Conditions
Interventions
Mirikizumab
Administered SC
Locations (5)
Fortrea Clinical Research Unit
Daytona Beach, Florida, United States
Axis Clinicals LLC
Dilworth, Minnesota, United States
Fortrea Clinical Research Unit
Dallas, Texas, United States
Worldwide Clinical Trials, Inc.
San Antonio, Texas, United States
Fortrea Clinical Research Unit
Madison, Wisconsin, United States